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In living systems iron appears predominantly associated with proteins, but can also be
detected in forms referred as labile iron, which denotes the combined redox properties of
iron and its amenability to exchange between ligands, including chelators.The labile cell iron
(LCI) composition varies with metal concentration and substances with chelating groups
but also with pH and the medium redox potential. Although physiologically in the lower
μM range, LCI plays a key role in cell iron economy as cross-roads of metabolic pathways.
LCI levels are continually regulated by an iron-responsive machinery that balances iron
uptake versus deposition into ferritin. However, LCI rises aberrantly in some cell types
due to faulty cell utilization pathways or inﬁltration by pathological iron forms that are
found in hemosiderotic plasma. As LCI attains pathological levels, it can catalyze reactive
O species (ROS) formation that, at particular threshold, can surpass cellular anti-oxidant
capacities and seriously damage its constituents. While in normal plasma and interstitial
ﬂuids, virtually all iron is securely carried by circulating transferrin (Tf; that renders
iron essentially non-labile), in systemic iron overload (IO), the total plasma iron binding
capacity is often surpassed by a massive iron inﬂux from hyperabsorptive gut or from
erythrocyte overburdened spleen and/or liver. As plasma Tf approaches iron saturation,
labile plasma iron (LPI) emerges in forms that can inﬁltrate cells by unregulated routes
and raise LCI to toxic levels. Despite the limited knowledge available on LPI speciation
in different types and degrees of IO, LPI measurements can be and are in fact used for
identifying systemic IO and for initiating/adjusting chelation regimens to attain full-day LPI
protection. A recent application of labile iron assay is the detection of labile components
in intravenous iron formulations per se as well as in plasma (LPI) following parenteral iron
administration.
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INTRODUCTION
The various forms of iron present in biological ﬂuids are
largely determined by the chemical composition of the medium,
particularly its reductive power (commonly dictated by the
GSH-NADPH/NADH levels) and the repertoire of substances
with metal complexing groups (e.g., carboxylates, phosphates,
amides, thiolates, and hydroxylates). In extracellular ﬂuids,
essentially all the iron is safely carried by the protein trans-
ferrin (Tf) that shields the Fe(III) from the environment and
renders it virtually redox-inactive as well as non-exchangeable
with, or displaceable by, physiological substances or metals.
Thus Tf-bound iron (TBI) is a tightly bound form of fer-
ric iron that by deﬁnition is non-labile and it remains as
such, until conformational changes triggered by binding of
Tf to its cognitive Tf receptor (TfR), in conjunction with
medium acidiﬁcation, jointly lead to its release and ensuing
reduction to ferrous iron (Crichton, 2001; Cairo and Recal-
cati, 2007). That complex series of reactions is mechanistically
integrated in the physiological process of receptor mediated
endocytosis (RME) of TBI that operates in all mammalian
cells and serves as the key route of regulated iron uptake
(Figure 1).
In cellular compartments almost all (>95%) of the iron is
also protein-bound, either directly to protein residues or via iron-
containing prosthetic groups such as heme or iron sulfur clusters
(ISC; Crichton, 2001). Although most of the iron-containing pro-
teins are endowed with catalytic metal centers, for this exposé we
consider the redox-active metal as stricto senso labile if it is also
physiologically exchangeable and/or pharmacologically chelat-
able. This ﬁts with the more traditional deﬁnition of labile cell
iron (LCI) that was introduced in order to describe transitory (i.e.,
exchangeable) forms of cell iron that are important for cell iron
metabolism and homeostasis (Jacobs, 1977; Crichton, 2001). We
describe here LCI in physiological and pathophysiological states
and its potential relevance to pharmacology and therapeutics.
Methodological aspects related to the analysis of LCI and its coun-
terpart in plasma, labile plasma iron (LPI), are the subject of other
reviews (Esposito et al., 2002; Kakhlon and Cabantchik, 2002;
Petrat et al., 2002; Kruszewski, 2003; Breuer et al., 2007; Brissot
et al., 2012).
LABILE CELL IRON
Many attempts made to chemically deﬁne LCI in extracts from
lysed cells led biochemists to implicate various Fe3+ complexes as
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potential LCI candidates [e.g., nucleotides and even glutathione
(GSH); Weaver and Pollack, 1989; Hider and Kong, 2011]. How-
ever, those implications should be interpreted with caution as
changes in environments (including pH and redox potential) that
result from cell de-compartmentalization are likely to result in
metal redistribution among potential metal binders. Therefore, in
this review we regard LCI as a dynamic parameter that is relevant
only for living cells and that prevails under deﬁned conditions,
spatial, temporal and environmental (Cabantchik et al., 2009).
PHYSIOLOGY
The most compelling evidence that LCI prevails in physiological
conditions in most mammalian cells, is the demonstrable abil-
ity of permeating iron chelators to inhibit the in situ (cell or
organelle) catalytic contribution of labile iron to basal as well as
peroxide-stimulated cell reactive O species (ROS) formation and
to inhibit iron-dependent cell functions (Glickstein et al., 2005).
LCI is per se a generic term used to describe labile iron in the cell
as a whole, or in particular cell compartments. The cytosolic and
organellar components of LCI are comprised of chelatable com-
plexes of both Fe2+and Fe3+, whose relative proportions largely
reﬂect (or are dictated by) the reductive properties and chem-
ical composition of the compartment in question and those in
turn depend on cell metabolism (Petrat et al., 2002; Breuer et al.,
2007).
The cytosolic LCI, that is “strategically” located at the cross-
roads of cell iron metabolism, serves both as metabolic source
of metal but also as indicator of cell iron levels. Thus, cells
sense and regulate LCI by balancing the uptake of circulating
TBI with the storage of unutilized (surplus?) cell iron in shells
of ferritin molecules (Figure 1). As expected for a dynamic
cell parameter, the various LCI pools are likely to vary over
time in response to chemical or biological stimuli as well as
to metabolic demands/responses. For example, in human K562
or murine erythroleukemia cells, exposure to increasing TBI
concentration results in a commensurate rise in cytosolic and
mitochondrial LI indicating increased iron uptake by RME and
ensuing release into cytosol (and almost concurrent delivery to
mitochondria; Shvartsman et al., 2007, 2010; Levi and Rovidac,
2009). Similar results are obtained by modulation of cell ferritin
expression (Picard et al., 1998; Kakhlon et al., 2001). Conversely,
LCI levels fall in iron starvation, following stable or transient
overexpression of cytosolic or mitochondrial ferritin as well as
in some mitochondrial disorders that involve aberrant mitochon-
drial iron accumulation (Rouault, 2006, 2012; Levi and Rovidac,
2009).
The search for putative LCI components have led also to com-
plementary searches for LCI counterparts, namely putative iron
chaperons or carriers that, in analogy with copper chaperons,
might mediate “safe” iron trafﬁc within cells via formation of
non-labile or occluded metal complexes. Accordingly, PBP pro-
teins were implicated as facilitators of iron incorporation into
ferritin (Shi et al., 2008) and 2,4 dihydroxybenzoate (2,4-DHB) as
universal cytosol-mitochondrial iron chaperon (Devireddy et al.,
2010). It must be stressed however, that: (a) neither the putative
presence of nM concentrations of 2,4-DHB, seemingly detected
in mammalian cells, nor (b) the almost undetectable chelating
ability of 2,4-DHB per se in buffered medium, let alone (c) in a
cellular milieu that is comprised of mM concentrations of organo-
phosphates and -carboxylates, could possibly confer upon DHB a
putative role as cell iron chaperon, carrier, or the like (Shvartsman
and Cabantchik, 2012). For hemoglobin synthesizing reticulo-
cytes, it was hypothesized that iron derived from uptake of TBI
by RME is delivered to mitochondria by a mechanism referred
as “kiss and run” (Zhang et al., 2005; Sheftel et al., 2007). In that
mechanism, vesicle-mitochondria interactions were proposed to
provide bridges or channels for trans-vesicular transfer of Fe2+ to
cytosol.
FIGURE 1 | Labile cell iron (LCI) and labile plasma iron (LPI). Proposed routes of labile iron ingress into cells comprise voltage dependent Ca channels
(VDCC; Oudit et al., 2006), the Zn transporter ZIP14 (Liuzzi et al., 2006) and others (Sohn et al., 2012).
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In live-cell ﬂuorescence studies done on human K562 ery-
throleukemia or murine erythroleukemia (MEL) cells, changes
in cytosolic LCI levels occurred in response to increasing con-
centrations of TBI (but also non-TBI (NTBI) compounds), and
almost in parallel to changes in mitochondrial LCI (Shvarts-
man et al., 2007, 2010). Those studies indicated the operation
of various routes of cell iron trafﬁc, most of which are man-
ifested as transient changes in the levels of the cytosolic LCI
pool. Observations describing a rapid delivery of iron from the
point of entry into cells to mitochondria have also been observed
in cells exposed to various NTBI substances (e.g., organic iron
salts; Shvartsman et al., 2007). Moreover, in the intestinal CACO-
2 cell model, iron trafﬁcked intracellularly from mucosal to serosal
cell phases appeared to be shielded in dimetal transporter 1
(DMT1)-containing endocytic vesicles (Núñez et al., 1994; Núñez
et al., 1999; Linder et al., 2006). Hitherto, the demonstration of
“cell iron passages” as “safe and efﬁcient” routes of iron delivery
mediated by cell chaperons or vesicles, awaits experimental sup-
port. However, their possible contribution to cell iron physiology
does not exclude cellular iron trafﬁc also (or primarily) via LCI
pools, whose levels are dynamically monitored live with metal-
sensing or redox-sensing probes in response to physiological
challenges.
PATHOLOGY
It is generally accepted that a major and persistent rise in LCI
levels can compromise cell integrity, since excessively accumu-
lated labile iron is prone to engage in the catalytic generation
of noxious ROS from reactive O intermediates (ROIs) and those
can override the cell antioxidant defenses (Figure 1; Kruszewski,
2003). These reactions occur primarily in mitochondria, which
not only tend to accumulate excessive LI in various disorders
but also suffer the consequences of local ROS formation and
ensuing damage. In the various types of systemic siderosis (pri-
mary or transfusional), the etiopathology of iron overload (IO)
is classically associated with the ability of components of the
hemosiderotic plasma to inﬁltrate cells and raise the LCI levels in
both cytosol and mitochondria (Kakhlon and Cabantchik, 2002;
Cabantchik et al., 2009). However, a unique feature in inherited
mitochondrial disorders caused by faulty biosynthesis/assembly
of heme or ISC is the under-utilization of iron that results in
mitochondrial iron accumulation/deposition and ensuing cytoso-
lic iron deprivation (Rouault, 2006, 2012; Breuer and Cabantchik,
2009; Camaschella, 2009; Li-Hsuan Huang et al., 2011). That
scenario of iron maldistribution (that might be causatively inter-
related) is promoted by a vicious circle of increased cell iron uptake
induced by a reduction in cytosolic LCI (Li-Hsuan Huang et al.,
2011). The latter in turn induces TfR expression via activation of
the iron-regulatory IRP-IRE system (Cairo and Recalcati, 2007),
leading to increased TfFe uptake and ensuing iron deposition
in mitochondria. The resulting phenotypes of regional sidero-
sis are demonstrated in sideroblastic anemia (SA) caused by the
mutated gene alas2 (for XLSA), or glrx5 (for SA) or slc25a38
(for SA) but also in neuro-siderosis caused by the mutated gene
fxn (for FRDA) or abcb7 (for x-linked SA with ataxia, xlsa/a;
Rouault, 2006, 2012; Camaschella, 2009; Li-Hsuan Huang et al.,
2011).
PHARMACOLOGY
To the extent that a persistently elevated LCI is a risk factor for
cell survival (Li-Hsuan Huang et al., 2011; Fleming and Ponka,
2012), metal detoxiﬁcation by chelation should be regarded as
FIGURE 2 | Aims of chelation therapy for systemic versus regional
siderosis. In systemic siderosis, primarily transfusional hemosiderosis
(thalassemia major, myelodysplastic syndrome-MDS, sickle cell
disease-SCD or Blackfan Diamond anemia-BDA), the major aim is to
reduce body iron burden by scavenging and disposing the iron that
accumulated in tissues and ﬂuids. In regional siderosis, iron
accumulation in particular cell compartments is accompanied by a
deﬁciency in another cell compartment (e.g., in various types of
sideroblastic anemia or the neurodegenerative disorders Friedreich
ataxia-FRDA), or the maldistribution of iron is between different organs.
For this cases, chelation is designed to redistribute the accumulated
iron within the same cells by direct scavenging and redeployment or via
transfer to extracellular transferrin (Tf) and recapture by
receptor-mediated endocytosis-RME.
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the most direct mode of pharmacological intervention (Hershko
et al., 2005; Pietrangelo, 2007; Porter, 2009; Ma et al., 2012; Cam-
aschella, 2013). However, such an approach should be endowed
with speciﬁcity for labile forms of iron and designed with an ade-
quate regimen so as not to generate long term metal deﬁciency,
local or systemic. In principle, the major goal of chelation is
the neutralization or attenuation of iron propensity for catalyz-
ing radical formation. In order for a chelator to meet that goal
in an iron overloaded tissue, it must be permeant to cells and
endowed with an effective binding afﬁnity for the labile metal (to
ensure speciﬁcity) and a mode of coordinating complexation that
should render the metal essentially non-labile. Those are exempli-
ﬁed by: (a) the tridentate chelator deferasirox (DFR) that binds
Fe3+ with 2:1 stoichiometry and (b) the bidentate deferiprone
(DFP) that binds it with 3:1 stoichiometry. As in systemic siderosis,
the targets of chelation are both within cells and in extracellular
ﬂuids, the goal of chelation is twofold: (a) metal detoxiﬁcation
by means of reducing the iron burden in overloaded tissues and
(b) prevention of tissue iron accumulation, by maintaining a
low level of LPI, namely the labile components of plasma NTBI
(Figure 2).
Unlike in systemic siderosis, in regional siderosis, iron is
generally maldistributed among cells or cell organelles, often
accumulating in some at the expense of iron-sufﬁcient ones.
Scavenging of accumulated iron by chelation might accomplish
regional detoxiﬁcation but also concurrently generate depriva-
tion in iron-sufﬁcient or iron-deﬁcient regions (e.g., tissues, cells,
or organelles; Breuer and Cabantchik, 2009). Thus, for regional
siderosis, treatment should not be limited to scavenging of surplus
iron but should be followed by its redeployment, either within
or across cells, as depicted in Figure 2. Such mode of metal
redistribution can be accomplished by chelators with siderophore
properties, namely membrane permeant chelators that have a
combined accessibility and iron afﬁnity for scavenging LCI in cell
and organelles but also the ability to transfer the chelated metal
to cell acceptors or the plasma iron acceptor Tf (Kakhlon and
Cabantchik, 2002; Breuer and Cabantchik, 2009). A paradigm for
that modus operandi is given by DFP, that in addition of scaveng-
ing and redeploying iron between cells and extracellular Tf, it has
also the ability to correct iron maldistribution per se (Sohn et al.,
2008, 2011; Breuer and Cabantchik, 2009; Kakhlon et al., 2010;
e.g., between mitochondria and cytosol, as found in cells rendered
frataxin deﬁcient by shRNA suppression technology) as well as
most of the affected cell properties (Kakhlon et al., 2008, 2010).
DETERMINATION OF LCI IN LIVING CELLS
The determination of LCI in living cells has been based on spec-
troscopic probes (herewith referred as ﬂuorescence metal sensors
FMS) that detect labile iron in situ and in real time by one of
the following mechanisms (Petrat et al., 2002; Glickstein et al.,
2006; Ma et al., 2006; Breuer et al., 2007): (a) reversible quench-
ing of ﬂuorescence upon binding of iron to a probe endowed
with a ﬂuorescent-tagged chelating unit or (b) generation of ﬂu-
orescence by metal-catalyzed oxidation of a ﬂuorogenic probe
(Glickstein et al., 2006; Ma et al., 2006). Changes in ﬂuorescence
signal are attributed to labile iron if they are prevented or reversed
by a strong and permeant iron chelator that can swiftly gain
FIGURE 3 | Principle of labile iron detection with fluorescent metal
sensors (FMS) using fluorescence microscopy imaging. Calcein blue
(CALB) as FMS paradigm. The blue ﬂuorescent umbelliferyl iminodiacetic
acid binds Fe(III) with a 2:1 or 3:1 stoichiometry and undergoes
ﬂuorescence (F) quenching which can be reversed by addition of excess
amounts of the chelator deferasirox (DFR). That process, schematically
depicted in the lower part of the ﬁgure, can be applied to cells (e.g., human
hepatic hepG2 cells) by loading them with the acetomethoxy ester
(CALB-AM) precursor that generates the ﬂuorescent CALB in the cytosol
(ﬂuorescence microscopy imaging, pseudcolor: blue represents relatively
low F signal and red high F signal). The addition of an excess amount of a
strong permeant chelator (e.g., deferasirox, DFR) leads to a rise in
intracellular ﬂuorescence F that denotes the amount of CALB-Fe
generated by binding of CALB to LCI. The observed F, which is
proportional to LCI, can be converted into actual concentration of iron
(Epsztejn et al., 1997; Esposito et al., 2002) that represents the cytosolic
LCI pool.
access to cell compartments and scavenge LCI as well as FMS-
chelated iron (!). FMSs like calcein blue (CALB as shown in
Figure 3) or calcein green (CALG as shown in Figure 4) are com-
prised of one or two metal chelating arms (aminodiacetate or
iminodiacetate) linked to ﬂuorescent probes (e.g., ﬂuorescein or
methylumbelliferone) that undergo signal quenching upon bind-
ing of transition metals like Fe or Cu. The probes can be easily
loaded into cells via membrane permeant precursors that are non-
ﬂuorescent and non-chelating, e.g., CALG-AM or CALB-AM;
AM-acetomethoxy. These probes are hydrolyzed intracellularly,
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FIGURE 4 | Calcein green (CALG) and RPA as FMS for simultaneous
assessment of Fe ingress into cytosol and mitochondria
(fluorescence microscopy imaging). The indicated ﬂuorescent FMSs
CALG (d) (loaded into the cell cytosol via the CALG-AM precursor) and
red RPA (f) (loaded into cell mitochondria by potentiometric distribution)
(a) were monitored with time by ﬂuorescence microscopy imaging.
Following addition of 5 μM ferric-hydroxyquinoline (1:1) for 10 min (b) the
ﬂuorescence intensity (in relative units) in both cytosol and mitochondria
dropped substantially (from a to b and a′ to b′ for CALG and RPA,
respectively). The reduction in the ﬂuorescence signal elicited by the
added Fe provides a measure for the amount of labile metal that gained
access to the cytosol in 10 min, until Fe ingress was stopped by
addition of 20 μM of the impermeant chelator DTPA-diethylenetriamine
pentaacetic acid (to chelate all extracellular Fe). Subsequent addition of
50 μM of the permeant chelator DFP, led to the recovery CALG
ﬂuorescence quenched by the added Fe as well the original LCI, denoted
by DFP. On the other hand, the quenched RPA signal was not
recovered by addition of DFP, due to the relatively poor reversibility of
phenanthroline-complexed metal in physiological conditions. g depicts the
principle of CALG use as FMS.
releasing the ﬂuorescent, impermeant chelating CALG (binds iron
1:1) or CALB (binds iron 2:1) that interact (reversibly) with resi-
dent labile iron and undergo quenching commensurate with LCI
concentrations. That mode of iron sensing is depicted schemat-
ically at the bottom of Figures 3 and 4 for CALB and CALG,
respectively, whereby iron added to the free CALB or CALG
quenches the FMS and addition of a relatively high concentra-
tion of a strong iron chelator restores the quenched ﬂuorescence.
In CALB-laden human hepatic HepG2 cells (Figure 3), the FMS
ﬁlls the cytosolic space and binds a fraction of LCI that can be
revealed upon addition of excess permeant chelator. Thus addi-
tion of DFR elicits a rise in ﬂuorescence F that corresponds to
Fe released form the quenched CALB-Fe the chelator (F can be
converted to actual concentration of LCI with the aid of appropri-
ate calibration curves as demonstrated earlier for CALG (Epsztejn
et al., 1997; Cabantchik et al., 2002; Petrat et al., 2002; Breuer et al.,
2007).
The principle of LCI measurement demonstrated with the
FMS CALB can also be used to assess dynamic changes in var-
ious LCI pools with organelle targeted FMS (Glickstein et al.,
2005; Shvartsman et al., 2007, 2010; Sohn et al., 2008; Porter,
2009; Cabantchik et al., 2013). Figure 4 depicts h9c2 cardiac cells
double labeled with CALG (cytosol and nucleus) and RPA, a
red rhodamine-phenanthroline iron-sensitive probe that targets
potentiometrically (binds iron 3:1) to mitochondria. Addition of
a permeant iron source reduces the ﬂuorescent intensity of both
CALG and RPA (indicating ingress of labile iron to the respective
compartment) and subsequent addition of the permeant chelator
DFP restores the quenched ﬂuorescence signal of CALG, but
not that of RPA (that binds iron tightly and demands extreme
conditions for scavenging the bound metal from the phenan-
throline:metal 3:1 complex). Parallel time-dependent changes in
cytosolic and mitochondrial LCI compartments can be moni-
tored by ﬂow cytometry or ﬂuorescence microscopy as means
to assess iron transport into the respective compartments in
response to addition of TBI or NTBI (Shvartsman et al., 2007,
2010). As demonstrated in Figure 5 for TBI, the relative time-
dependent changes in ﬂuorescence intensity obtained for either
CALG or RPA by ﬂow cytometry match those obtained inde-
pendently by ﬂuorescence microscopy imaging. Figure 5 depicts
both the resident cytosolic LCI prior to and after addition of
TBI (labeled LCI and LCI+, respectively) that are revealed as
changes in CALG ﬂuorescence after addition of the permeant tri-
dentate chelator (salicylaldehyde isonicotinoyl hydrazone SIH).
When time-dependent proﬁles are done on probe labeled cells
exposed to different substrate concentrations, it is also possible to
obtain the kinetic parameters of iron ingress into the respective
LCI pools (cytosolic and mitochondrial), by converting ΔF to LCI
concentrations, as described elsewhere (Shvartsman et al., 2007,
2010).
Various types of FMS have been applied to cells as sensors for
monitoring changes in LCI by following stoichiometry quenching
of ﬂuorescence (Rauen et al., 2007; Prus and Fibach, 2008a,b; Ma
et al., 2012). Among those are probes based on phenanthroline,
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FIGURE 5 | Example of simultaneous tracing of Fe ingress (from TfFe)
into cytosol and mitochondria of human K562 cells by flow cytometry
(FC) and front-face fluorescence (plate reader; modified from
references Shvartsman et al., 2010; Shvartsman and Cabantchik, 2012).
The ﬂuorescent FMSs calcein green (CALG) and RPA are loaded into K562
cells as described in previous ﬁgures, the ﬁrst in the cytosol and the
second in mitochondria (depicted schematically in the center of the
ﬁgure). Fluorescence intensity (F) is followed with time at different time
points by FC or continuously by spectroﬂuorimetry in a ﬂuorescence plate
reader using wavelength settings for ﬂuorescein (CALG) and rhodamine
(RPA). The left panel depicts schematically the FC proﬁles of cell samples
taken at different times following addition TfFe (only F for green
ﬂuorescent calG is shown; arrow indicated median F values). The right
panel shows values of F at different time points (following addition of
TfFe or none, as indicated) normalized for values of F at t time 0 (F /F0)
for both CALG (black lines) and RPA (red broken lines) as obtained in a
ﬂuorescence plate reader. The arrows indicate the normalized (to time 0)
median ﬂuorescence values obtained in the left panel (indicated by
arrows). The relatively ﬂat lines represent the mean values in cells not
exposed to Tf, to indicate the extent of probe leakage during the
measurements. In order to assess the basal LCI level (no TfFe added) and
that raised by Fe (from TfFe) after 75′ exposure to TfFe, we obtain a
measure of CALG-Fe both in basal conditions (no TfFe added) and at a
given time point following addition of TfFe (75′). The measure of CALG-Fe
is obtained by addition of a strong permeant iron chelator SIH
(salicyl-isonicotinoyl-hydrazone) that scavenges Fe from CALF-Fe raising
CALG ﬂuorescence intensity commensurately. The F obtained by addition
of SIH provides a measure of LCI.
deferrioxamine, or hydroxypyridinones chelating moieties and
others originally designed for monitoring intracellular Ca. The
major shortcoming of most those probes is the difﬁculty in revers-
ing the quenched signal in physiological conditions and thereby
the difﬁculty in unequivocally assigning the quenched signal to in
situ LCI.
Targeted FMSs have also been used to demonstrate intracel-
lular redistribution of iron (scavengery and redeployment) by
addition of the chelator siderophore DFP in a cell model of iron
maldistribution (Kakhlon et al., 2008; Sohn et al., 2008, 2011).
As depicted in Figure 6, h9c2 cells, were pre-labeled with the
FMSs RPA (red, for mitochondria) and the ﬂuorescence quenched
histone-CALG-Fe (green, for the nucleus) and incubated with the
bidentate chelator DFP. As schematized in the lower panel, an
increase in nuclear ﬂuorescence elicited by added DFP denotes
iron scavengery from the CALG-Fe moiety, whereas a decrease in
RPA ﬂuorescence denoted DFP-mediated redeployment of Fe to
mitochondria. As some DFP-Fe might also egress from cells into
a medium containing apo-Tf, iron can redeployed to Tf, that in
turn can also deliver the metal to other cells. This is depicted in
the right panel, whereby the medium from the h9c2 cells treated
with DFP offered to iron-deﬁcient erythroid MEL cells supported
hemoglobin Hb synthesis.
An additional mode of monitoring LCI in living cells is by
assessing the ability of labile iron to catalyze oxidation of ﬂuoro-
genic analogs of dihydroﬂuorescein or dihydrorhodamine loaded
into cells. In the presence of ROIs (spontaneously generated in
the cell or prompted by addition of oxidants like H2O2 or other
peroxides) the labile metal converts in situ the non-ﬂuorescent
dihydro-probes into the respective ﬂuorescent probes. As with the
other FMS, the contribution of LCI to the time-dependent genera-
tion of ﬂuorescence is assessed by the degree of inhibition attained




In systemic IO, plasma is the compartment that harbors the
pathophysiological source of uncontrolled iron ingress into cells
and ensuing tissue IO (Hershko et al., 1978, 2005; Graham et al.,
1979; Pietrangelo, 2007). The most implicated component of that
source is LPI (Graham et al., 1979), the plasma counterpart of
LCI that represents the labile fraction of plasma NTBI (Breuer
et al., 2000; Esposito et al., 2003). As LPI comprises the redox-
active and exchangeable forms of iron in native plasma that are
also direct pharmacological targets of chelation (Pootrakul et al.,
2004), it represents a parameter with potential diagnostic as well as
therapeutic (i.e., theragnostic) value (Cabantchik et al., 2013). The
generic term NTBI was originally introduced to denote the non-
physiological, lowmolecularweight formsof iron that is not tightly
associated with Tf and appears in plasma of IO patients (Hershko
et al., 1978; Graham et al., 1979). Those forms were postulated on
the basis that iron levels in plasma of IO patients often supersede
total iron binding capacity (TIBC). Since a substantial fraction
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FIGURE 6 | Intracellular and transcellular redistribution of iron. The
proof of principle of intracellular scavengery and redeployment is
depicted schematically in the lower part of the ﬁgure, whereas the
upper part depicts the experimental results as visualized by
ﬂuorescence microscopy imaging. Murine h9c2 cardiomyocytes were
double labeled with ﬂuorescent metal sensors: red RPA in mitochondria
and green histone-CALG precomplexed to Fe (that partially quenches the
probe ﬂuorescence) in the nucleus. Addition of the chelator-siderophore
deferiprone (DFP), leads to (1) the scavenging of the Fe from hCAL-Fe,
manifested as an increase in nuclear ﬂuorescence and (2) a
concomitant quenching of mitochondrial-RPA red ﬂuorescence, that
denotes the redeployment of Fe from the intracellular generated DFP-Fe
chelate. In addition, DFP-Fe chelates that egress from cells (2′) can
transfer the Fe to extracellular apotransferrin (Tf) and the latter (3) in
turn, can furnish the metal to Fe-deﬁcient murine erythroleukemia cells
(MEL) and thereby support hemoglobinization. All the described steps
were experimentally demonstrated in references (Sohn et al., 2008,
2011).
of NTBI is apparently adsorbed to plasma proteins, its chemical
detection has posed technical difﬁculties in native plasma/serum
unless pretreated with metal mobilizing agents like the polycar-
boxylate nitrilotriacetate (NTA) or diethylenetriamine pentaacetic
acid (DTPA; Hershko et al., 1978; Graham et al., 1979; Singh
et al., 1990; Gosriwatana et al., 1999; Kolb et al., 2009). Although
several tests have been performed to ascertain that the applied
extraction measures do not generally lead to some mobilization
of Tf iron, those claims have been challenged leading to the
application of more gentle mobilization conditions (Kolb et al.,
2009). However, in general, most mobilizing maneuvers applied
to plasma/sera that contains any of the chelators used in clinical
practice, can lead to mobilization from highly saturated Tf (Kolb
et al., 2009). A more serious difﬁculty pertains to the use of the
generic term NTBI to denote plasma iron forms that are unique
to IO and presumed to be potentially toxic. Deﬁning “something
that is by what it is not” (classically known as an apophasis, from
Greek α′πóϕασις), can be confusing and in practice oxymoronic.
For example, plasma that does not contain pathological species
contains in fact NTBI in the form of ferritin or iron-chelates gen-
erated during iron chelation therapy or polymeric iron that is
given supplementary via parenteral routes and detected in plasma
by NTBI assays. On the other hand LPI is a parameter that
denotes, operationally, the level of labile iron species in native
plasma/serum irrespective of treatment or medium composition,
an asset that can also become a liability if plasma/serum is not
properly stored or some components of serum that affect its
redox properties undergo extreme modiﬁcations (Breuer et al.,
2012).
Attempts were done to identify the membrane transport mech-
anisms involved in NTBI uptake into cells that cause IO and
oxidative damage. However, few studies took into consideration
: (a) the actual repertoire of iron permeant species (i.e., the iron
complexes that comprise the iron overloaded plasma containing
NTBI) and their relative concentrations at different degrees of
IO, (b) the composition of the medium milieu (e.g., the presence
of high protein that limits substrate availability and redox-active
substances that affect substrate composition) and (c) the different
transport agencies present in different cell types. Those agencies
comprise a variety of transporters or carriers of metals or metal-
complexes, ionic channels or even the means for non-speciﬁc
adsorptive endocytosis. As most NTBI transport studies have only
been done with model simulating substrates in protein-free media
and with model cells, their relevance to the etiopathology of tissue
iron accumulation in systemic IO remains to be experimentally
demonstrated (Figure 1). Recent studies indicated dimeric and
oligomeric iron-citrate complexes as potential NTBI candidates
(Evans et al., 2008), although the chemical speciation is likely to
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FIGURE 7 | Principles of determination of LPI and of plasma NTBI.
Plasma/serum non-TBI (transferrin bound iron) indicated as NTBI is
measured by the three indicated methodologies. NTBI is measured by its
extraction (1) from serum with relatively high (10–80 mM) concentrations of
nitrilotriacetic acid (NTA), size ﬁltration (2) and iron detection by colorimetric
methods or by addition of iron complexing agents and analysis by HPLC.
The labile plasma iron (LPI) component of NTBI is analyzed by exposing
native plasma or serum to physiological concentration of ascorbate in the
presence of the ﬂuorogenic dihydrorhodamine (DHR), whose
time-dependent conversion from non-ﬂuorescent (NF) to green (F)
ﬂuorescent 1,2,3, rhodamine (R) is followed in a plate reader (or in a
ﬂuorimeter) and the fraction of the signal change inhibited by
deferrioxamine (or another strong and speciﬁc iron chelator) is attributed to
labile iron. Performance of LPI measurements in the presence of
0.1–1.0 mM NTA, provides an equivalent estimate of NTBI (Breuer et al.,
2012). The directly chelatable iron (DCI) component of NTBI is assessed
with a strong ﬂuorescent (F) chelator such as
ﬂuoresceinated-deferrioxamine (FDFO) that upon binding of Fe(III)
undergoes stoichiometric quenching to non-ﬂuorescent (NF) chelate
FDFO-Fe.
vary with the level of IO and the natural history of the disease in a
given patient (Silva and Hider, 2009). Likewise, NTBI association
with plasma proteins is exacerbated in oxidative conditions, such
as those that prevail under inﬂammation or in chronic diabetes
(Arezes et al., 2013). A single study with T lymphocytes demon-
strated that oligomeric ferric citrate is taken up by T lymphocytes
(Arezes et al., 2013) and another study indicated that a substantial
fraction of iron that accumulated from exposure of cells to NTBI-
containing human plasma was by adsorptive endocytosis (Sohn
et al., 2012).
DETERMINATION OF LPI/PLASMA NTBI
The measurement of a few μM of plasma NTBI in the presence of
70 to >100% saturated TBI (30–50 μM) poses some methodolog-
ical problems. Two different approaches have tried to overcome
them (schematically depicted in Figure 7): (1) by extraction of
plasma NTBI with iron mobilizing/extraction/chelating agents
like NTA or DTPA followed by size ﬁltration (to separate NTBI
from TBI) and detection of the iron by iron complex formation
and direct measurement of colored complexes or following HPLC
analysis (Singh et al., 1990; Gosriwatana et al., 1999; Kolb et al.,
2009) and (2) by the detection of LPI in native plasma/serum
by: (a) prompting resident LPI (with physiological concentrations
of ascorbate) to either catalytically convert the non-ﬂuorescent
probe dihydrorhodamine (DHR) into the ﬂuorescent rhodamine
(R; Esposito et al., 2003) or co-catalyze with bleomycin chem-
ical changes in chromophoric substrates (Halliwell et al., 1988;
Evans and Halliwell, 1994) or (b) binding the labile iron with a
ﬂuorescent-chelator that undergoes a commensurate quenching
of ﬂuorescence, as exempliﬁed in Figure 7 with ﬂuoresceinated
DFO (FDFO; Breuer et al., 2001). For either modality (a or b) of
method 2, a speciﬁc iron chelator (DFO or DFP in excess) is added
to a parallel sample in order to assess the speciﬁc contribution of
labile iron to the observed change in ﬂuorescence elicited in the
test sample.
The LPI/NTBI assays have been used extensively to monitor
chelation efﬁcacy in transfusional siderotic patients treated with
different chelators (Cabantchik et al., 2005; Daar et al., 2009; Zan-
ninelli et al., 2009; Greenberg et al., 2010; Danjou et al., 2014) or
hemochromatosis patients following phleboptomy (Le Lan et al.,
2005), particularly for establishing: (a) the attainment of sufﬁ-
ciently low LPI (<0.1 μM) at trough levels of chelator as a goal
of a particular therapeutic regimen (Cabantchik et al., 2005; Zan-
ninelli et al., 2009) an the appearance of LPI as a criterion for
initiating chelation therapy in polytransfused children (Danjou
et al., 2014). An attempt has also been done to compare differ-
ent assays for assessing NTBI (not LPI; Jacobs et al., 2005) but a
newer completed one that included also LPI should provide more
comprehensive and updated information regarding the usefulness
of the LPI/NTBI assays in the clinical setting.
CONCLUSION AND PERSPECTIVES
With presently available methodologies based on FMS, it has
become possible to obtain real time measures of LCI and their
compartments in both physiological and pathological condi-
tions (i.e., systemic and regional siderosis) and of LPI/NTBI
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in body ﬂuids as early marker of systemic IO and treatment
efﬁcacy. Of particular importance is the ability to assess bio-
logical responses to pharmacological measures (e.g., intravenous
iron supplementation or iron chelation) and correlate them with
clinical outcomes. That area still needs further strengthening,
particularly in establishing the thresholds of changes in LPI
and LCI that deﬁne a given pathological state, either overt or
impending.
Unfortunately, hitherto, it has been difﬁcult to deﬁne the chem-
ical components of LCI and LPI in biological systems, largely
because of their heterogeneous character and variable nature of the
media they dwell in. The same pertains to hypothesized iron chap-
erons that might be operative in mammalian cells and play some
physiological role in intracellular iron trafﬁc and metabolism.
Although LCI is the parameter closely associated with tissue iron
accumulation and ensuing iron-dependent damage, from the
clinical perspective, only LPI has thus far proven diagnostically
therapeutically relevant for assessing impending/emerging IO and
therapeutically, for initiating chelation and monitoring its short
term and long term efﬁcacy.
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